Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - OxySure Therapeutics, Inc.v308817_ex99-1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported) April 6, 2012
 
OxySure Systems, Inc.
(Exact name of registrant as specified in its chapter)
 
Delaware
(State or other jurisdiction
of incorporation
000-54137
(Commission
File Number)
71-0960725
(IRS Employer
Identification No.)

 

10880 John W. Elliott Drive, Suite 600, Frisco, TX

(Address of principal executive offices)

75033
(Zip Code)
   

 

(972) 294-6450

Registrant's telephone number, including area code

 
___________________________________________
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 8.01. Other Events

 

On April 6, 2012, OxySure Systems, Inc (“OxySure” or the “Company”) issued a press release announcing a conference call to discuss recent developments and financial results. A copy of the press release is furnished with this report as Exhibit 99.1.

  

Such information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

  

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibit 99.1 Press Release dated April 6, 2012.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 9, 2012

 

  OXYSURE SYSTEMS, INC.,
  a Delaware corporation
     
     
     
    /s/ Julian T. Ross
  BY: Julian T. Ross
  ITS: Chief Executive Officer, President,
  Chief Financial Officer, and Secretary
     

 

 

2